In-vitro cyclosporin sensitivity of proliferating lymphocytes is predictive of in-vivo therapeutic response in ulcerative colitis

Citation
G. Mccormack et al., In-vitro cyclosporin sensitivity of proliferating lymphocytes is predictive of in-vivo therapeutic response in ulcerative colitis, ALIM PHARM, 15(5), 2001, pp. 665-668
Citations number
14
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology,"da verificare
Journal title
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
ISSN journal
0269-2813 → ACNP
Volume
15
Issue
5
Year of publication
2001
Pages
665 - 668
Database
ISI
SICI code
0269-2813(200105)15:5<665:ICSOPL>2.0.ZU;2-Z
Abstract
Background: The efficacy of cyclosporin in the management of ulcerative col itis is recognized. Not all patients respond to this treatment. Existing cl inical and laboratory parameters are of little use in identifying those mos t likely to respond. Aims: To determine whether in-vitro sensitivity to cyclosporin as measured by a lymphocyte proliferation assay is predictive of in-vivo response to th erapy, Methods: The study comprised seven responders with ulcerative colitis, seve n non-responders, and 14 healthy matched controls. A lymphocyte proliferati on assay was carried out in the presence of a range of concentrations of cy closporin and a dose-response curve constructed for each subject. The IC50 value, the concentration of cyclosporin that resulted in 50% inhibition of proliferation, was calculated for each subject. IC50 values for responders, non-responders and controls were compared using a Mann-Whitney test. Results: There was a wide range of values obtained for the study group as a whole, IC50 values for nonresponders were significantly higher than those of responders (P < 0.05). Conclusions: There is a population-wide variation of in-vitro sensitivity t o cyclosporin. This is reflected in in-vivo sensitivity as measured by clin ical response to cyclosporin treatment. Future therapeutic strategies need to address this inherent variability of individual response to therapy.